covid 19 presentation slides

Unsupported browser

This site was designed for modern browsers and tested with Internet Explorer version 10 and later.

It may not look or work correctly on your browser.

15 Best Free Covid Coronavirus & Virus PowerPoint PPT Templates 2024

Whether you need to make a Covid-related or any other medical presentation, one thing is certain. It’s much faster to start with a coronavirus PowerPoint template than trying to do it from scratch. 

Luckily, there are plenty of free and premium Covid and virus-themed PPT templates available online that you can use as a starting point. 

The Best Source for COVID Coronavirus and Virus PowerPoint Templates (With Unlimited Use)

Envato Elements is the best place to find premium coronavirus, Covid, and virus PowerPoint templates with professional designs. Envato Elements is a subscription-based marketplace. It gives you access to thousands of creative assets — for a single monthly fee:

• premium PowerPoint templates for all your presentation needs
• stock photos and royalty-free music that you can use in your presentations
• fonts, icons, and more to customize your presentation

Explore Virus PowerPoint Templates Now

Envato Elements gives you the best bang for your buck if you need PowerPoint templates and other design assets regularly. Unlike our premium templates, free PowerPoint designs often lack features and customization options.

Top 5 Premium Covid and Coronavirus PowerPoint Templates From Envato Elements for 2024

Before we show you the best free PowerPoint templates with virus themes, here are the top premium coronavirus PowerPoint templates from Envato Elements:

1. Delta Corona Virus PowerPoint Template

First, we've got the Delta Corona Virus PowerPoint template with a modern and clean design. This Covid slides template features 80+ slides. They've got all the necessary content ideas for you to create an engaging presentation.

The template also comes with handmade infographic elements. It was designed in HD resolution and comes in dark and light versions.

2. Covid-19 Virus - Medical PowerPoint Template

The Covid-19 is a medical PowerPoint template with more than 70 unique and modern slides. This Covid presentation template has a gorgeous duotone color scheme, but you can easily customize it to match your brand. You’ll also find unique mockup devices, image placeholders, infographic elements, and more. The template comes in widescreen resolution. 

3. Covirus - Disease & Virus PowerPoint Template

Here’s a unique and trendy Covid and virus PowerPoint template that'll make creating your presentation a breeze. The template comes with 33 unique slides. You can customize colors, fonts, and even the slide layout to create the perfect presentation. You’ll also find image and media placeholders, vector-based icons, and mockup devices. 

4. Secure Virus 19 Medical PowerPoint Template

This coronavirus PPT has twenty-five unique slides. It can help you deliver a comprehensive presentation. Finding the right color scheme for your business won't be a problem. Included are over ninety color schemes that are fully customizable.

You'll find much-needed infographics, vectors, and charts as well. Download this complete Covid PowerPoint template.

5. Covid Virus - Medical PowerPoint Template

This Covid presentation template gives you the power to create an eye-catching presentation. Included are forty-six slides that feature modern designs. Many graphics are included to help you deliver a compelling presentation to your audience. Free web fonts are included, and you can drag and drop in images of your choice to any slide.

The premium templates mentioned are some of the highest quality available. If you're on a budget, you may not be able to afford the premium templates. In this next section, we'll go over the top free PowerPoint templates virus. 

15 Top Free Covid Coronavirus & Virus PowerPoint Templates to Download

Before looking for a free Covid PowerPoint template on the web, check Envato's free offerings first. Try out various premium template files (not always PowerPoint files) at no cost to you.

Here's the deal: 

With that in mind, here are the best free coronavirus and virus PowerPoint templates that you can find and download online for your presentation: 

1. Free Social Distance PowerPoint Template

With the help of this coronavirus PowerPoint template for free, you’ll have no problem explaining social distancing rules. The Covid PowerPoint template includes four pre-designed slides.

2. Medicine Health Care PowerPoint Templates

Try this medicine and healthcare PowerPoint template if you’re looking for a modern template. Use it to present all the necessary information about Coronavirus or any other medical emergency.

3. Medical Laboratory PowerPoint Templates

Here’s a free template virus that would be perfect for any type of virus research presentation. The template comes with individual slides as well as section covers. It includes 25 slides.

4. Coronavirus Pandemic PowerPoint Templates

Share important findings and information about Coronavirus or any other virus with this modern template. It comes with three master slides that you can customize.

5. Covid-19 Coronavirus PowerPoint Templates  

This free Covid PowerPoint template has a dark green background with virus icons. Use it to quickly create a presentation. The template comes with three master slides designed in several resolutions.

6. Infection PowerPoint Templates

Use this fun infection PowerPoint template to create a presentation about virus research or to provide more information about a specific virus. The Coronavirus PPT includes three master slides that you can duplicate to create your presentation.

7. Free COVID-19 Vaccine PowerPoint Template

With the help of this free PowerPoint template with a virus theme, you can easily share all the information people need to know about Covid-19 vaccines. The Covid vaccine theme PowerPoint comes with four slides.

8. Free COVID-19 Presentation Template

Use this Covid presentation template to create a presentation that shares information about the virus and how to fight it. The template has four master slides that you can copy as many times as you need.

9. Free Covid PowerPoint Template

Here’s a minimal and simple COVID PowerPoint template. It features an image that shows the virus spreading all over the world. It also contains four master Covid PowerPoint slides that you can copy for your presentation. 

10. Free COVID PowerPoint Background

Consider this free COVID PowerPoint background for your presentation. It features an image of a word game spelling out coronavirus, pandemic, and virus. 

11. Medical Illustrated. Free PowerPoint Template & Google Slides Theme

Here’s another minimal and clean PowerPoint template. Use it for any type of medical presentation. The Covid presentation template comes with 25 slides.

12. Blue Medical. Free PowerPoint Template & Google Slides Theme

The blue color in this medical and virus PowerPoint template conveys professionalism. It comes with 25 covid PowerPoint slides.

13. Medical Virus. Free PowerPoint Template & Google Slides Theme

This coronavirus PowerPoint template for free can be used for sharing information about the virus and how to prevent the spread. The template comes with 25 slides that you can duplicate, re-order, and delete as you see fit.

14. Free COVID-19 Health System Capacity Curve PowerPoint

Use this free Covid-19 PowerPoint template to showcase the virus's effect on the health system capacity. The template includes several different slide variations.

15. Coronavirus PowerPoint Template

Use this coronavirus PowerPoint template for free to create informative presentations about coronavirus measures, treatments, and protection. It comes with several slides, including section cover and agenda slides. 

How to Make a Coronavirus Presentation in PowerPoint

1. Choose the Right Slides

Not all the slides in the template will work for your presentation. Go through each slide and pick the ones that pertain to your presentation. For the slides, you don't want to use, left-click the slide and choose Delete Slide .

2. Add In Your Content

Now it's time to add in your presentation's content. Have a document open with all the text you want to use for each slide. Then copy and paste the text to each slide.

Each slide has text placeholders. Double-click the placeholder text and select all the text. You can then paste in your text.

3. Add In Your Images

Next, we'll add in our images to make the presentation more visually appealing. Just like the text, there are also image placeholders. To add in your images, click the image icon on each slide. Your computer files pop up. Choose the image you want to add. 

4. Add in Animations

To help add professional polish to your presentation, we'll add in animations. Choose the top menu header that says Animations . From there, choose the animation that you want to have on your slides. To see what each animation looks like, choose the Preview button on the far left side of the menu.

5. Proofread Your Presentation

Often this step is skipped. We get caught up in making our design look perfect and forget to proofread our presentation. Having grammatical errors and misspelled words is the quickest way to make your presentation look unprofessional. Take the time to go over every slide in your presentation before calling it done.

5 Quick Tips To Make Virus-Themed PPT Presentations in 2024

You’ve just seen the best free and premium coronavirus slideshow templates. Now, here are a few quarantine PowerPoint ideas that'll help you design a standout presentation: 

1. Stand Out With Custom Icons and Illustrations

Custom icons and illustrations make your presentation more memorable. Not to mention, they'll make your presentation stand out. The Covid-19 PowerPoint template features modern custom vector graphics that you can use as inspiration.

2. Keep the Text to a Minimum

Don’t overwhelm your audience by adding a lot of text on your slides. This can cause them to read the slide before you’re done presenting it and they may become disengaged. Instead, keep the text to a minimum of one to three bullet points per slide.

3. Use a Professional Color Scheme

You don’t have to shy away from color in your presentation. Make sure that your color scheme is professional and doesn’t contain any clashing colors. You can draw inspiration from this modern Coronavirus Medical PowerPoint template from Envato Elements.

4. Use Charts for Complex Data and Statistics

If you've got a lot of complex data and statistics, consider using charts and infographic elements to represent them. This will make it easier for your audience to understand and absorb the information.

5. Customize the Slides With Your Photos

Using stock photos is a great way to make your presentation more memorable. But you can achieve an even better effect by including photos of you, your team, and your employees. A template like the Corona Virus PowerPoint Template has plenty of image placeholders for you to use.

Discover More Top PowerPoint Template Designs

If you want to see even more PowerPoint template examples or if you need to create a different type of presentation, look at the following template roundups:

Common PowerPoint Questions Answered (FAQ)

If you're creating a Coronavirus PPT presentation and you're not familiar with PowerPoint, you may have some questions. We've got you covered! Here are some common PowerPoint questions and their answers:

1. I'm New to PowerPoint, What Should I Know?

PowerPoint is a powerhouse presentation software. But learning just the basics of the software enables you to create a complete presentation. Check out our ultimate PowerPoint guide to learn these basics.

2. How Should I Design My Slides?

The visual hierarchy of the slides dictates the design. The arrangement of the elements on your page and how they're placed has the biggest effect on what your audience remembers. Your slide's colors, typography, and images used are major contributors to the design of your slides. 

3. Can I Collaborate on One Presentation?

PowerPoint Online makes collaboration possible. This makes it easy to delegate separate tasks that need to be completed for the presentation. For an in-depth guide on how to collaborate as a team, view the article below.

4. What Colors Should I Use In My Coronavirus PPT?

The colors that work well are blue and red. Red helps highlight the urgency and danger of the virus and blue helps build trust with your audience. If your business has a set of brand colors, then you can use these colors as well. 

5. Can I Print Out My Slides?

Yes, you can! Print out your slides may be necessary depending on where you're presenting. Check out the tutorial below for a complete guide on how to print out your slides.

Learn More About Making Great PowerPoint Presentations in 2024

The tips we shared above are only a small selection of what makes a great presentation. If you want to learn more about designing and writing great PowerPoint presentations , check out the tutorials below: 

Create a Coronavirus Presentation Quickly With Templates

If you need to create a presentation about Coronavirus or any other type of medical presentation, there's no shortage of free PowerPoint templates with a virus theme to choose from. But, if you want to make your presentation look more unique, don’t forget to check out premium templates. 

Stop by Envato Elements if you know you’ll be needing PowerPoint templates and other creative assets on the regular or if you've got multiple brands to promote. 

Editorial Note: This post has been updated with contributions from Daniel Strongin . Daniel is a freelance instructor for Envato Tuts+.

Related Resources

Contagious Chronicles: Updated Recommendations for Respiratory Season

In this episode, NFID experts discuss updated recommendations to help protect against COVID-19, influenza (flu), respiratory syncytial virus (RSV), and pneumococcal disease …

Sonya’s Story (COVID-19)

A daughter prays that her mother’s death helps others understand the dangers of COVID-19

Contagious Chronicles: Don’t Be A Dreaded Spreader

In this episode, NFID experts offer insights on updated recommendations from the Centers for Disease Control and Prevention (CDC) to help prevent the spread of respiratory viruses, including COVID-19, influenza (flu), and respiratory syncytial virus (RSV)

• DynamicPowerPoint.com
• SignageTube.com
• SplitFlapTV.com

Coronavirus Tips PowerPoint Template

Mar 28, 2020 | Data Dashboards , DataPoint , DataPoint Real-time Screens , Healthcare

To help with the current coronavirus emergency, we have put together these free coronavirus tips Powerpoint slide templates for you to use. The slides include coronavirus prevention tips, symptoms and instructions on what to do if you have symptoms.

Feel free to adjust the templates based on your local health authority instructions and contact information. Download the templates by providing your name and email address below.

Coronavirus Tips – Symptoms

This slide shows the common coronavirus symptoms and gives patients instructions on what to do if they have symptoms so that they don’t go to the hospital or doctor in a panic and overload the local health system. You can edit this slide or add additional slides to add local phone numbers, websites or other resource information.

nice template

I would like to download and amend the COVID slides please.

Solved over chat. Now you can use the presentation. Good luck with it!

I would like to download the template as well.

Did you sign up Nicole? That should be working. Check your spam folder maybe.

Excellent template , I will use for professional and public presentations.

Great to read. Thanks.

Submit a Comment

Your email address will not be published. Required fields are marked *

Pin It on Pinterest

• StumbleUpon
• Print Friendly

• Privacy Overview
• Strictly Necessary Cookies

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

One Time Code

< Go back to Login

Forgot Password

Please enter your registered email ID. You will receive an email message with instructions on how to reset your password.

COVID-19 Templates

•   Animated Flow Chart - 4x3  –  $9.99
•   Animated Flow Chart - 16x9  –  $9.99

Animated Flow Chart PowerPoint Template

A flow chart is a diagram of the steps in a process and their sequence. It is used to document a process for better understanding, quality contro....

•   Covid-19-Timeline-05 - 4x3  –  $4.99
•   Covid-19-Timeline-05 - 16x9  –  $4.99

COVID-19 Timeline Template for PowerPoint and Google Slides 05

COVID-19 Timeline Template for PowerPoint and Google Slides 05 The Covid-19 Timeline Template shows the timeline of Covid-19 symptoms and treatme....

•   Covid 19 Timeline 04 - 4x3  –  $6.99
•   Covid 19 Timeline 04 - 16x9  –  $6.99

COVID-19 Timeline Template for PowerPoint and Google Slides 04

COVID-19 Timeline Template for PowerPoint and Google Slides 04 The COVID-19 Timeline Template is meant to track and present a timeline of importa....

•   COVID 19 Business Impact Presentation - 4x3  –  $19.99
•   COVID 19 Business Impact Presentation - 16x9  –  $19.99

COVID-19 Business Impact Presentation PowerPoint Template

About COVID-19 Business Impact Presentation PowerPoint Template The recent coronavirus pandemic has forced many businesses and industries to stop....

•   Change Management PowerPoint Theme - 4x3  –  $19.99
•   Change Management PowerPoint Theme - 16x9  –  $19.99

Change Management Theme PowerPoint Template

About Change Management Theme PowerPoint Template With the help of change management theme PowerPoint template, you can introduce a new way of th....

•   Contact-Tracing-PowerPoint-Template - 4x3  –  $4.99
•   Contact-Tracing-PowerPoint-Template - 16x9  –  $4.99

Contact Tracing PowerPoint Template

Contact Tracing Presentation Template Use this Contact Tracing PowerPoint template to create visually appealing presentations in any professional....

COVID(Coronavirus)-19 Impact PowerPoint Template

Download the Free COVID-19 Impact PowerPoint presentation to share with your senior management and customers. COVID-19 has impacted businesses ma....

Project Mitigation Plan Detailed PowerPoint Template

Free Project Mitigation Plan Detailed Presentation Template Use this Free Project Mitigation Plan Detailed PowerPoint template to create visually....

•   Digital Business Process Transformation - 4x3  –  $6.99
•   Digital Business Process Transformation - 16x9  –  $6.99

Digital Business Process Transformation PowerPoint Template

This professional presentation template is a minimalist yet modern template designed to help businesses and organizations effectively to showcase....

•   COVID Crisis Response - 4x3  –  $4.99
•   COVID Crisis Response - 16x9  –  $4.99

COVID Crisis Response PowerPoint Template

COVID Crisis Response Presentation Template Use this COVID Crisis Response PowerPoint template to create visually appealing presentations in any ....

•   COVID-19 Global Update Dashboard - 4x3  –  $4.99
•   COVID-19 Global Update Dashboard - 16x9  –  $4.99

COVID-19 Global Update Dashboard PowerPoint Template

COVID-19 Global Update Dashboard Presentation Template Use this COVID-19 Global Update Dashboard PowerPoint template to create visually appealing....

•   Change Managment Business Framework - 4x3  –  $4.99
•   Change Managment Business Framework - 16x9  –  $4.99

Change Managment Business Framework PowerPoint Template

Change Management Business Framework Presentation Template Use this Change Management Business Framework PowerPoint template to create visually a....

Related Presentations

Clinical trials.

7 templates >

4 templates >

2 templates >

286 templates >

Patient Journey

8 templates >

COVID 19 PowerPoint Templates For Presentations:

The COVID 19 PowerPoint templates go beyond traditional static slides to make your professional presentations stand out. Given the sleek design and customized features, they can be used as PowerPoint as well as  Google Slides templates . Inculcated with visually appealing unique and creative designs, the templates will double your presentation value in front of your audience. You can browse through a vast library of COVID 19 Google Slides templates,  PowerPoint themes  and  backgrounds  to stand out in your next presentation.

Product Pricing

What is a covid 19 powerpoint template.

A COVID 19 PowerPoint template is a ready-made presentation template that provides a structured framework for creating professional COVID 19 presentations. The COVID 19 PPT presentation template includes design elements, layouts, and fonts that you can customize to fit your content and brand.

How To Choose The Best COVID 19 Presentation Templates?

Keep the following points in mind while choosing a COVID 19 Presentation template for PowerPoint (PPT) or Google Slides:

• Understand your presentation goals and objectives.
• Make sure the COVID 19 template aligns with your visual needs and appeal.
• Ensure the template is versatile enough to adapt to various types of content.
• Ensure the template is easily customizable.

Are COVID 19 PowerPoint Templates Compatible With Google Slides?

Yes, all our COVID 19 presentation templates are compatible and can be used as COVID 19 Google Slides templates.

What Are The Advantages Of COVID 19 Presentation Templates?

COVID 19 PPT presentation templates can be beneficial because they:

• Add multiple visual and aesthetic layers to your slides.
• Ensure that complex information, insights and data is presented in a simplistic way.
• Enhance the overall visual appeal of the content.
• Save you a lot of time as you don’t have to start editing from scratch.
• Improve the professional outlook of your presentation.

Can I Edit The Elements In COVID 19 PowerPoint Templates?

Yes, our COVID 19 PowerPoint and Google Slides templates are fully editable. You can easily modify the individual elements including icons, fonts, colors, etc. while making your presentations using  professional PowerPoint templates .

How To Download COVID 19 PowerPoint Templates For Presentations?

To download COVID 19 presentation templates, you can follow these steps:

• Select the resolution (16*9 or 4*3).
• Select the format you want to download the COVID 19 template in (Google Slides or PowerPoint).
• Make the payment (SlideUpLift has a collection of paid as well as free COVID 19 PowerPoint templates).
• You can download the file or open it in Google Slides.

Forgot Password?

Privacy Overview

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

We use cookies on this website to enhance your experience. You can find out more about how we use cookies here

Preventing COVID-19: Refresher Presentations for Schools and Childcare Settings

Understanding how COVID-19 is transmitted and ensuring that proper public health measures are in place is important for preventing the spread of COVID-19 in schools and childcare settings. This presentation series provides those working in school and childcare settings a refresher about the public health practices that help prevent and control the spread of COVID-19. Implementing all recommended public health measures is important to help prevent the spread of COVID-19 in your facilities (i.e., no single measure should be relied on by itself).  Below you will find links to the recorded presentations as well as a downloadable copy of the presentation slides.

COVID-19 Transmission

An overview of how COVID-19 is spread, measures to reduce the risk of spread and implications for infection prevention and control (IPAC) in schools and child care settings.

• Duration: 9 min
• Updated 3 Sep 2021
• View the full transcript

Presentation

Hand Hygiene

Hand Hygiene: The Importance of Cleaning Hands

• Duration: 8 min

The role of cleaning your hands in preventing the spread of COVID-19 as well as review of the proper technique for cleaning your hands and hand care.

Physical Distancing

Environmental Cleaning

• Duration: 7 min

Considerations for cleaning and disinfecting surfaces in school and child care settings.

Communications

[email protected]

• Media Centre

Don’t have a MyPHO account? Register Now

You must be logged in and have the correct access level to access this product.

Login or Register

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List

Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID)

Ekaterina pazukhina.

1 Laboratory of Health Economics, Institute of Applied Economic Studies, The Russian Presidential Academy of National Economy and Public Administration, Moscow, Russia

2 Center for Advanced Financial Planning, Macroeconomic Analysis and Financial Statistics, Financial Research Institute of the Ministry of Finance of the Russian Federation, Moscow, Russia

Margarita Andreeva

3 Department of Paediatrics and Paediatric Infectious Diseases, Institute of Child’s Health, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Ekaterina Spiridonova

Polina bobkova, anastasia shikhaleva, yasmin el-taravi, mikhail rumyantsev, aysylu gamirova, anastasiia bairashevskaia, polina petrova, dina baimukhambetova, maria pikuza, elina abdeeva, yulia filippova, salima deunezhewa, nikita nekliudov, polina bugaeva, nikolay bulanov.

4 Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Sergey Avdeev

5 Clinic of Pulmonology, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Valentina Kapustina

6 Department of Internal Medicine №1, Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Alla Guekht

7 Research and Clinical Center for Neuropsychiatry, Moscow, Russia

8 Pirogov Russian National Research Medical University, Moscow, Russia

Audrey DunnGalvin

9 School of Applied Psychology, University College Cork, Cork City, Ireland

Pasquale Comberiati

10 Department of Clinical and Experimental Medicine, Section of Pediatrics, University of Pisa, Pisa, Italy

Diego G. Peroni

Christian apfelbacher.

11 Institute of Social Medicine and Health Systems Research, Faculty of Medicine, Otto von Guericke University Magdeburg, Magdeburg, Germany

Jon Genuneit

12 Pediatric Epidemiology, Department of Pediatrics, Medical Faculty, Leipzig University, Leipzig, Germany

Luis Felipe Reyes

13 Universidad de La Sabana, Chía, Colombia

14 Clínica Universidad de La Sabana, Chía, Colombia

Caroline L. H. Brackel

15 Department of Pediatric Pulmonology, Emma Children’s Hospital, Amsterdam University Medical Centers, Amsterdam, the Netherlands

16 Department of Pediatrics, Tergooi MC, Hilversum, the Netherlands

Victor Fomin

17 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Andrey A. Svistunov

Peter timashev.

18 Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Lyudmila Mazankova

19 Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

Alexandra Miroshina

20 ZA Bashlyaeva Children’s Municipal Clinical Hospital, Moscow, Russia

Elmira Samitova

Svetlana borzakova.

21 Research Institute for Healthcare Organization and Medical Management of Moscow Healthcare Department, Moscow, Russia

Elena Bondarenko

Anatoliy a. korsunskiy, gail carson.

22 Nuffield Department of Medicine, ISARIC Global Support Centre, University of Oxford, Oxford, UK

Louise Sigfrid

Janet t. scott.

23 MRC-University of Glasgow Centre for Virus Research, Glasgow, UK

Matthew Greenhawt

24 Department of Pediatrics, Section of Allergy/Immunology, Children’s Hospital Colorado, University of Colorado School of Medicine, Aurora, USA

Danilo Buonsenso

25 Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

26 Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy

27 Center for Global Health Research and Studies, Università Cattolica del Sacro Cuore, Roma, Italia

Malcolm G. Semple

28 Health Protection Research Unit in Emerging and Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK

29 Department of Respiratory Medicine, Alder Hey Children’s Hospital, Liverpool, UK

John O. Warner

30 Inflammation, Repair and Development Section, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK

Piero Olliaro

Dale m. needham.

31 Outcomes After Critical Illness and Surgery (OACIS) Research Group, Johns Hopkins University, Baltimore, MD USA

32 Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD USA

33 Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD USA

Petr Glybochko

Denis butnaru, ismail m. osmanov, daniel munblit, associated data.

The data that support the findings of this study are available from the corresponding author, DM, upon reasonable request.

Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors.

Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge.

One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47–53) in adults and 20% (95% CI 16–24) in children at 6 months, with decline to 34% (95% CI 31–37) and 11% (95% CI 8–14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47).

Conclusions

Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12916-022-02448-4.

Although most people fully recover from acute infection with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) and coronavirus disease 2019 (COVID-19) disease, some experience ongoing sequelae [ 1 ]. This wide range of symptoms occurring in the weeks to months after SARS-CoV-2 infection has been referred to as either long COVID, post-COVID-19 condition, or post-acute sequelae of SARS-CoV-2 infection (PASC), amongst other names [ 2 ]. High profile editorials [ 3 , 4 ] drew attention to an increasing number of people experiencing these ongoing sequelae and called for comprehensive research, including risk factors and clinical features.

Most post-COVID research has focused on adults [ 5 ], given the predominance of adult COVID-19 in the first pandemic waves, which appeared to spare children, somewhat. Therefore, there is a more limited number of paediatric studies [ 6 ], although the need for research on COVID-19 consequences in children and young people has been previously acknowledged and has grown in importance with emergence of variants that are affecting children [ 7 ]. Head-to-head comparison of COVID-19 sequelae in children and adults is still lacking.

Many studies have investigated the prevalence and risk factors of long COVID [ 5 ], but heterogeneity in patient assessment and definitions [ 8 ] and lack of data regarding symptom duration are challenges to meta-analyses. Notably, in September 2020, the World Health Organization (WHO) Classification and Terminologies unit created International Classification of Diseases 10 (ICD-10) and ICD-11 codes for post-COVID-19 condition, and in October 2021, a clinical case definition of post-COVID-19 condition was announced, following a Delphi consensus process [ 9 ]. It was defined as a condition occurring “in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis”. However, this definition was intended for adults, and WHO suggests that a separate definition might be applicable for children.

This prospective study aimed to investigate the prevalence and characteristics of post-COVID-19 condition in previously hospitalised children and adults using standardised follow-up data collection protocols developed by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Global Adult and Paediatric COVID-19 follow-up working groups.

The study is reported based on the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist for cohort studies ( https://www.strobe-statement.org/ ), which can be found in the supplementary material.

Study design, setting, and participants

This study combines data from two longitudinal prospective cohorts of patients with COVID-19: (a) adults admitted to Sechenov University Hospital Network (four large tertiary adult hospitals) in Moscow, Russia, and (b) children admitted to Z.A. Bashlyaeva Children’s Municipal Clinical Hospital in Moscow, Russia (the primary paediatric COVID-19 hospital in Moscow throughout the time of pandemic). Only patients with positive polymerase chain reaction (PCR) confirmed SARS-CoV-2 infection were included in this study. Details regarding the demographic profile, hospitalisation requirements and origination of these cohorts are comprehensively described elsewhere [ 10 , 11 ]. In brief, to form and define the cohorts, the acute phase data of adult and paediatric patients were extracted from electronic medical records (EMR) and the Local Health Information System (HIS) at the host institutions using ISARIC Core case report form (CRF) for acute phase data collection. The acute-phase datasets included demographics, comorbidities, symptoms on admission, computed tomography results, and disease severity, including use of supportive therapies.

Data collection and entry were performed by a team of trained medical students and physician residents, with extensive relevant research experience, via telephone interviews and the Research Electronic Data Capture (REDCap) database [ 10 – 12 ], with supervision by senior academic researchers.

Given the well-recognised emergence of COVID-19 infection sequelae, this follow-up study was planned to track prevalence and risk factors for the development of such sequelae occurring after hospital discharge. Data were obtained at two follow-up points, at 6 (± 2) and 12 (± 2) months after hospital discharge. These follow-up assessments, collected via telephone interviews, used the Tier 1 ISARIC Long-term Follow-up Study CRF for adult patients and version 1 of the ISARIC COVID-19 Health and Wellbeing Follow Up Survey for Children for paediatric patients, both developed by the ISARIC Global COVID-19 follow-up working group and independently forward and backward translated into Russian. These follow-up assessments evaluated patients’ physical and mental health status and assessed for any newly developed symptoms between hospital discharge and the follow-up assessment, including symptom onset and duration as previously described [ 11 ]. Given the well-recognised emergence of post-COVID infection sequelae, this follow-up study was planned to track prevalence and risk factors for the development of such sequelae occurring after hospital discharge.

The acute-hospitalisation dataset included demographics, symptoms, comorbidities (at the time of hospital admission for COVID-19), chest computed tomography (CT) results, supportive care required, and clinical outcomes at the time of discharge.

Data management

REDCap electronic data capture tools (Vanderbilt University, Nashville, TN, USA) hosted at Sechenov University and Microsoft Excel (Microsoft Corp, Redmond, WA, USA) were used for data collection, storage, and management [ 13 , 14 ].

Definitions

Post-COVID-19 condition was defined as the presence of any symptom which started no later than three months after hospital discharge and lasted for at least 2 months as per the WHO case definition [ 9 ]. Symptom duration was calculated from the time of the hospital discharge in the absence of reliable objective medical record data regarding date of first symptoms appearance.

Patients requiring non-invasive ventilation, invasive ventilation, or intensive care unit (ICU) care during acute phase of COVID-19 were defined as severe.

Symptoms were categorised into nine manifestations: cardiovascular, dermatological, fatigue, gastrointestinal, musculoskeletal, neurocognitive, respiratory, sensory, and sleep (Table S 1 ). Symptom categorisation was based on previously published literature and ISARIC working groups’ discussion [ 10 , 11 ].

Statistical analysis

Descriptive statistics were calculated for baseline characteristics. Continuous variables were summarised as median (interquartile range, IQR) and categorical variables as frequency (percentage). 95% confidence intervals (CIs) were obtained for the estimates of post-COVID-19 condition prevalence using bootstrap methodology (10,000 iterations).

Forest plots were used to present the prevalence of post-COVID-19 condition and different manifestations. Circular dendrograms were used to illustrate coexistence of post-COVID-19 condition manifestations. The phenotypes of post-COVID-19 condition were presented using radial plots. The cut-off for defining a phenotype presentation was set at 2% of respondents reporting multiple manifestations. For children, due to a low number of respondents reporting multiple manifestations, all individuals were presented on the plots.

We included all participants with post-COVID-19 condition in the final analysis, without missing data imputation. In order to control for recall bias at 12-month follow-up, we considered post-COVID-19 condition manifestations only amongst those manifestations which were reported at 6-months and satisfied the WHO definition of post-COVID-19 condition. Only patients completing both 6-month and 12-month follow-up were included in this study analysis similarly to previously published large cohort studies [ 15 ].

Multivariable logistic regression analysis was performed separately for adults and children to investigate associations of demographic characteristics and comorbidities at hospital admission with COVID-19 (limited to those variables reported in > 3% of study participants) and severity of COVID-19 with post-COVID-19 condition prevalence at the time of the follow-up interviews. Selection of the variables was the following: “COVID-19 severity” variable as exposure, “post-COVID-19 condition” as an outcome, comorbidities as covariates, gender, and age as effect modifiers. Twelve variables in adults and seven in children were tested as potential risk factors based on data availability and previous research [ 10 , 11 , 15 – 18 ]. We included all participants for whom the variables of interest were available in the final analysis, without imputing missing data. Odds ratios were calculated together with 95% CIs.

Two-sided p -values were reported for all statistical tests, a p -value below 0.05 was considered to be statistically significant. Statistical analysis was performed in R version 4.0.2 using libraries dplyr, foreign, forestplot, ograph, and ggraph [ 19 ].

Out of 2509 eligible adults and 849 eligible children with laboratory confirmed COVID-19 discharged between April and August 2020, 1994 (79%) and 832 (98%) had contact information, and of these, 1013 (40% of discharged, 51% of those with contact information) adults and 360 children (42% of discharged, 43% of those with contact information) participated in both follow-up interviews and were included in the final analysis (Fig.  1 ). The 6-month follow-up interviews were conducted between November 2020 and March 2021 and the 12-month follow-up between April 2021 and August 2021.

Flow diagram of patients admitted with PCR-confirmed COVID-19 to Sechenov University Hospital Network (adults) and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital (children)

Table  1 shows the demographic and clinical characteristics of the study participants. For adults the median time, after hospital discharge, to the 6- and 12-month assessments was 215 days (IQR 196–235) and 383 days (IQR 376–390). The median age of adult patients was 56.8 years (IQR 47.0–65.8), and 49% (500/1013) were male. The most common pre-existing comorbidity in adults at admission was hypertension (45%, 458/1013), followed by chronic cardiac disease and excessive weight and obesity (20% each, 198/1013) and type II diabetes (15%, 148/1013). Three percent of patients (27/1013) required non-invasive ventilation, invasive ventilation, or ICU care during hospitalisation.

Demographic characteristics of adults admitted to the Sechenov University Hospital Network and children admitted to the Z.A. Bashlyaeva Children’s Municipal Clinical Hospital. Data are n (%) or median (IQR) excluding missing values. ICU, intensive care unit

For children, the median time to the 6-month follow-up was 255 days (IQR 223–270) and to the 12-month follow-up 367 days (IQR 351–379). The median paediatric patient age was 9.5 years (IQR 2.4–14.8), and 48% (174/360) were male. Three percent of children (12/360) required non-invasive ventilation, invasive ventilation, or treatment in the ICU during hospitalisation. The most common comorbidities in children were allergic rhinitis (7%, 26/360) and intestinal problems (7%, 25/360).

Figure  2 shows the temporal trend in post-COVID-19 condition manifestations prevalence. Prevalence was significantly higher in adults compared with children at both 6-month and 12-month follow-up ( p  < 0·001): relative risk of any manifestation 2.51 (2.02 to 3.11) at 6 months and 3.07 (2.26 to 4.16) at 12 months. The difference in prevalence of each specific manifestation between adults and children is shown in tables S 2 and S 3 . The proportion of individuals with at least one post-COVID-19 condition manifestation decreased from 50% (95% CI 47–53) at 6 months to 34% (95% CI 31–37) at 12 months in adults and from 20% (95% CI 16–24) to 11% (95% CI 8–14), respectively, in children. A decline in prevalence was observed across all manifestations.

Forest plots demonstrating the prevalence of post-COVID-19 condition manifestations in adults and children 6 and 12 months after hospital discharge. Sixth-month prevalence is coloured in red, and 12-month prevalence is coloured in blue. Estimates of the prevalence 95% confidence intervals were calculated using the bootstrapping method

In adults, the most common post-COVID-19 condition features at 6-month follow-up included fatigue 25% (95% CI 22–28), respiratory 22% (95%CI 20–25), neuro-cognitive 19% (95% CI 17–21), and dermatological 13% (95% CI 11–15) manifestations. At 12 months after the hospital discharge, the prevalence decreased to 12% (95% CI 10–14), 10% (95% CI 8–11), 9% (95% CI 7–11), and 4% (95% CI 3–5) respectively.

In children, the most common post-COVID-19 condition features at 6-month follow-up were fatigue 9% (95% CI 6–13), dermatological 5% (95% CI 3–7), neuro-cognitive 4% (95% CI 2–6), and sleep-related 4% (95% CI 2–6) manifestations. At the 12-month follow-up, these decreased to 4% (95% CI 2–6), 2% (95% CI 1–4), 2% (95% CI 1–3), and 1% (95% CI 0–1) respectively.

We investigated the phenotypes of post-COVID-19 condition in adults and children, defined as a report of two or more different manifestations at 6-month assessment (Figs.  3 and ​ and4). 4 ). Amongst adults, 28% (287/1013) reported at least two manifestations. We differentiated three prevalent phenotypes at 6 months, namely (a) fatigue/respiratory without neurological manifestations (10%, 29/287); (b) fatigue/respiratory with neurological manifestations (7%, 19/287); and (c) fatigue/neurological without respiratory manifestations (6%, 17/287), regardless of other manifestations reported. By 12 months, 41% (12/29) of people with fatigue/respiratory without neurological manifestations fully recovered, while only 21% (4/19) of fatigue/respiratory with neurological manifestations and 24% (4/17) of fatigue/neurological without respiratory manifestations were symptom-free (Additional file  1 : Figure S1).

Interrelations between the post-COVID-19 condition manifestations in adults and children 6 and 12 months since hospital discharge. Bubble diameter is proportional to the proportion of individuals with the symptom category reported. Line thickness is proportional to the number of individuals with the coexisting manifestations. Cardiovascular, CRD; dermatological, DRM; fatigue, FTG; gastrointestinal, GST; musculoskeletal, MSC; neurocognitive, NRL; respiratory, RSP; sensory, SNS; sleep, SLP

A Radial plots representing post-COVID-19 condition phenotypes in adults at 6 months after discharge and 12 months after discharge. Manifestations are shown for each patient; each segment represents a single patient. Thick black lines are used to distinct phenotypes. Cardiovascular, CRD; dermatological, DRM; fatigue, FTG; gastrointestinal, GST; musculoskeletal, MSC; neurocognitive, NRL; respiratory, RSP; sensory, SNS; sleep, SLP. B Radial plots representing post-COVID-19 condition phenotypes in children at 6 months after discharge and 12 months after discharge. Manifestations are shown for each patient; each segment represents a single patient. Thick black lines are used to distinct phenotypes. Cardiovascular, CRD; dermatological, DRM; fatigue, FTG; gastrointestinal, GST; musculoskeletal, MSC; neurocognitive, NRL; respiratory, RSP; sensory, SNS; sleep, SLP

In children, phenotypes were less feasible to assess due to a smaller case count of post-COVID-19 condition. Seven percent (25/360) of children had a combination of manifestations at 6-month follow-up. The only characteristic phenotype amongst individuals with coexisting manifestations was fatigue/neurological (24%, 6/25), with 50% (3/6) of these having fully resolved by 12 months.

Risk factors association with post-COVID-19 condition 6- and 12-months after hospital discharge were assessed in multivariable regression analysis separately for adults and children (Fig.  5 ).

A Multivariable logistic regression model demonstrating risk factors associated with post-COVID-19 condition in adults at 6-month follow-up. Odds ratios and 95% CIs are presented. B Multivariable logistic regression model demonstrating risk factors associated with post-COVID-19 condition in adults at 12-month follow-up. Odds ratios and 95% CIs are presented. C Multivariable logistic regression model demonstrating risk factors associated with post-COVID-19 condition in children at 6-month follow-up. Odds ratios and 95% CIs are presented. D Multivariable logistic regression model demonstrating risk factors associated with post-COVID-19 condition in children at 12-month follow-up. Odds ratios and 95% CIs are presented

In adults, female sex was the only statistically significant risk factor of post-COVID-19 condition at both 6-month (odds ratio of 2.04 (95% CI 1.57 to 2.65) and 12-month (2.04, 1.54 to 2.69) follow-up. Pre-existing hypertension was also (1.42, 1.04 to 1.94) independently associated with post-COVID-19 condition at 12 months only.

In children, pre-existing neurological comorbidities were associated with post-COVID-19 condition at both 6-months (4.38, 1.36 to 15.67) and 12 months (8.96, 2.55 to 34.82). History of allergic respiratory diseases was a risk factor (2.66, 1.04 to 6.47) for post-COVID-19 condition at 12 months only.

This prospective cohort study with 1013 adults and 360 children, who were previously hospitalised with laboratory confirmed SARS-CoV-2 infection, assessed the 6- and 12-month prevalence of post-COVID-19 condition, according to the WHO case definition, along with phenotypes and risk factors. We found that half of adults and one of five children had post-COVID-19 condition at 6 months follow-up, with fatigue being the most common manifestation. Although prevalence of post-COVID-19 condition declined between 6- and 12-month assessment, one in three adults and one in ten children still had sequelae. Post-COVID-19 condition was experienced by both sexes, with a higher risk amongst adult women. Pre-existing hypertension (adults) and pre-existing neurological comorbidities and allergic respiratory diseases (children) were associated with post-COVID-19 condition.

The prevalence of post-COVID-19 condition was significantly higher in adults and the risk of post-COVID-19 condition was 2.5 and 3 times higher in adults relative to children 6 and 12 months post-hospital discharge, respectively. This was true also for individual symptom groups, except gastrointestinal at 6 months, and cardiovascular, dermatological, and gastrointestinal at 12 months. Although persistent symptoms of COVID-19 have been assessed in many studies [ 5 ], most published research was performed prior to the WHO post-COVID-19 case definition [ 9 ] in absence of agreed terminology and associated data heterogeneity. With differences in methodology, outcome definitions, and absence of symptom duration measurement across cohorts, it is difficult to evaluate the prevalence of post-COVID-19 condition. Another limitation in the existing literature is the inadequate knowledge of COVID-19 sequelae in children [ 6 ] and the lack of direct head-to-head comparison of its features and prevalence in adults and children, which do not allow for complete understanding if manifestations behave differently based on age.

Persistence of symptoms is a worrisome issue, with half of the adults in our study reported post-COVID-19 condition at 6 months, and 34% still experiencing one or more manifestations 12 months after discharge. This finding is consistent with data from China, which reported a high rate of single sequelae symptom prevalence and decrease from 68% at 6 months to 49% at 12 months [ 15 ]. Difference in prevalence may be related differences in post-COVID condition definitions, as the Chinese study was published before the WHO case definition announcement. We found a twofold decrease in the prevalence of post-COVID-19 condition from 20% between 6 and 12 months in children. To our knowledge, this is the first study reporting consequences of COVID-19 in children 1 year after acute episode, though we did detect persistent symptoms 6 months after hospital discharge in children in a previous study especially in older children and those with allergic disease [ 11 ]. Fatigue was the most common manifestation in both children and adults, regardless of the follow-up time point, though proportionally more adults than children reported fatigue. This finding is consistent with prior data [ 5 , 6 ]. In adults and children, respiratory manifestations were reported in 20% and 2%, respectively. This difference may be related to greater severity of viral pneumonia in adults, as well as greater baseline respiratory comorbidity [ 20 ]. More frequent incidental infection rates may also confer some degree of non-specific immunological protection but the association with pre-existing respiratory allergy suggests that allergic hypersensitivity and/or auto-immune responses are involved. More research into pathophysiology and immune mechanisms is required to establish the cause of described association.

One third of individuals with post-COVID-19 condition can be classified by a phenotypes, of combined manifestations. One in five can be characterised by a combination of fatigue and respiratory with or without neurological manifestations. These results are similar to those reported by Taquet and colleagues [ 21 ]. We found that people without neurological manifestations become asymptomatic by 12 months more frequently than those reporting neurological manifestations at 6 months. However, due to a limited number of individuals available for phenotyping, it is premature to make any definitive conclusions.

The risk of post-COVID-19 condition was twice as high in female as in male adult patient at both time points, in line with previous studies assessing persistent symptoms [ 15 , 17 , 22 ]. Pre-existing hypertension was associated with post-COVID-19 condition at 12 months in adults. The association between pre-existing hypertension and higher risk of post-COVID-19 condition 12 months after hospital discharge in adults has not been previously reported [ 23 ], which may be explained by the difference in outcome definition. Pre-existing neurological comorbidities and allergic respiratory diseases were associated with post-COVID-19 in children. While allergic diseases are felt to be protective of developing COVID-19, this may become a risk factor for the sequelae development and merits further consideration. It was previously hypothesised that allergic conditions may increase the risk of long-term consequences following COVID-19 and that eosinophils, mast cells, or Th-2 responses may be potentially involved in the immunopathology of post-COVID-19 condition [ 24 ], but large prospective studies with biological material collection are required to confirm this.

This study has both strengths and limitations. Strengths include the following: (1) using of standardised ISARIC Long-term Follow-up Study CRFs for adults and children; (2) using the WHO post-COVID-19 condition definition; (3) enrolling both adults and children and comparing the two cohorts; and (4) a relatively large sample size of people attending both the 6- and 12-month follow-up visits, one of the longest follow-up assessments of hospitalised patients to-date. Limitations include the following: (1) questions about spectrum composition, as we enrolled only patients from Moscow (which may limit generalisability), a low proportion of whom had severe COVID-19—issues shared with most major COVID-19 cohort studies. This limitation is balanced by their otherwise being a paucity of data from eastern Europe regarding any COVID-19 outcomes, which becomes a novelty; (2) acute data were collected from the electronic medical records with no access to additional information that could be potentially retrieved from the medical notes—we mitigated potential inaccuracies of demographic information reported by the patients/parents/carers at the time of the hospital admission with subsequent verification during follow-up telephone interviews. This is an accepted and common limitation of cohorts assembled using this methodology; (3) a low proportion of patients with severe COVID-19 patients amongst both adults and children in our cohort limits the generalisability of the study findings to hospitalised patients with more mild to moderate COVID-19; (4) parents/caregivers were interviewed in this study and not children themselves, which is an accepted limitation of paediatric research conducted in children of a particular age; (5) a risk of potential selection bias, for instance with those with symptoms more likely to agree to survey and thus overestimating the prevalence of post-COVID-19 condition [ 25 ], as only 68% of adults and 62% of children for whom we had contact information agreed to participate in our study, and 51% and 42% respectively completing both visits—although retention of over 40% is generally considered good and rates here are comparable or higher than in the recent similar cohort studies [ 15 , 26 ]. Any attrition from a cohort may result in a substantial overestimation of the prevalence of post-COVID-19 condition as those who do remain in the cohort may represent a biased sample [ 25 ]. However, we did not find significant differences between respondents and non-respondents (Table S 4 ); (6) telephone interviews were used in this study, and we acknowledge that face-to-face interviews and/or objective measurements would deliver more robust results. However, financial and pandemic restrictions did not allow for this; (7) the study used hospitalised patients’ data. Interpretation of the data gathered from such sample may be prone to collider bias, as the sample is non-random as is conditions on hospital admission.

We used the ISARIC/WHO Clinical Characterisation Protocol, a prospective pandemic preparedness protocol which is agnostic to disease and has a pragmatic design to allow recruitment during pandemic conditions. As we already underlined in previous publications, the reality of conducting research in outbreak conditions is such that appropriate co-enrolment of a control group is practically challenging, primarily because COVID-19 has overshadowed other infections which could be used as comparators, and because of the lack of agreement on a commonly accepted control group [ 10 ].

This study has shown that half of adults and one of five children have post-COVID-19 condition, as per WHO case definition, 6 months after hospital discharge, with fatigue being the most common manifestation. Respiratory manifestations also were a major problem in adults. Although the prevalence of post-COVID-19 condition declined, one in three adults and one in ten children still had manifestations at 12 months follow-up. Post-COVID-19 condition was more common adult women and amongst adults with pre-existing hypertension. In children, pre-existing neurological comorbidities and allergic respiratory diseases were associated with post-COVID-19 condition. Future studies should define COVID-19 as per the new WHO case definition to allow for a better comparability. Further investigation of risk factors and underlying physiological and immunological mechanisms merit further consideration.

Acknowledgements

We are very grateful to the Sechenov University Hospital Network and Z.A. Bashlyaeva Children’s Municipal Clinical Hospital clinical staff and to the patients, parents, carers and families for their kindness and understanding during these difficult times of COVID-19 pandemic. We would also like to thank UK Embassy in Moscow for providing a grant. We would like to express our very great appreciation to ISARIC Global COVID-19 follow-up working group for the survey development. We would like to thank Mr Maksim Kholopov for providing technical support in data collection and database administration. We are grateful to Daria Bessonova, Olga Burencheva, Natalia Chepelova, Natalia Gorbova, Rina Grigoryan, Sapiat Isaeva, Alena Khrapkova, Ildar Khusainov, Tatiana Kokorina, Margaret Kvaratskheliya, Daria Levina, Anna Lunicheva, Margarita Mikheeva, Elizaveta Mikhsin, Roman Movsisyan, Veronika Palchikova, Maxim Privalov, Tatiana Reznikova, Olga Sokova, Ivan Timchenko, Anna Zezyulina, and Mikhail Zhilinsky for their help at different stages of the project. We are very thankful to FLIP, Eat & Talk, Luch, Black Market, and Academia for providing us the workspace in time of need and their support of COVID-19 research. Finally, we would like to extend our gratitude to the Global ISARIC team, the ISARIC global adult and paediatric COVID-19 follow-up working group, and ISARIC Global support centre for their continuous support and expertise and for the development of the outbreak ready standardised protocols for the data collection.

Sechenov StopCOVID Research Team:

Nikol Alekseeva, Elena Artigas, Asmik Avagyan, Lusine Baziyants, Anna Belkina, Anna Berbenyuk, Tatiana Bezbabicheva, Vadim Bezrukov, Semyon Bordyugov, Aleksandra Borisenko, Maria Bratukhina, Ekaterina Bugaiskaya, Julia Chayka, Yulia Cherdantseva, Natalia Degtyareva, Olesya Druzhkova, Alexander Dubinin, Khalisa Elifkhanova, Dmitry Eliseev, Anastasia Ezhova, Aleksandra Frolova, Julia Ganieva, Anastasia Gorina, Cyrill Gorlenko, Elizaveta Gribaleva, Eliza Gudratova, Shabnam Ibragimova, Khadizhat Kabieva, Yulia Kalan, Margarita Kalinina, Nadezhda Khitrina, Bogdan Kirillov, Herman Kiseljow, Maria Kislova, Natalya Kogut, Irina Konova, Mariia Korgunova, Anastasia Kotelnikova, Karina Kovygina, Alexandra Krupina, Anastasia Kuznetsova, Anna Kuznetsova, Baina Lavginova, Elza Lidjieva, Ekaterina Listovskaya, Maria Lobova, Maria Loshkareva, Ekaterina Lyubimova, Daria Mamchich, Nadezhda Markina, Anastasia Maystrenko, Aigun Mursalova, Evgeniy Nagornov, Anna Nartova, Daria Nikolaeva, Georgiy Novoselov, Marina Ogandzhanova, Anna Pavlenko, Olga Perekosova, Erika Porubayeva, Kristina Presnyakova, Anna Pushkareva, Olga Romanova, Philipp Roshchin, Diana Salakhova, Ilona Sarukhanyan, Victoria Savina, Jamilya Shatrova, Nataliya Shishkina, Anastasia Shvedova, Denis Smirnov, Veronika Solovieva, Olga Spasskaya, Olga Sukhodolskaya, Shakir Suleimanov, Nailya Urmantaeva, Olga Usalka, Valeria Ustyan, Yana Valieva, Katerina Varaksina, Maria Varaksina Ekaterina Varlamova, Maria Vodianova, Margarita Yegiyan, Margarita Zaikina, Anastasia Zorina, Elena Zuykova.

Abbreviations

Authors’ contributions

DM, DBu, and IMO conceptualised the project and formulated research goals and aims. EP, MA, ESp, PBo, PBu, NN, AS, YET, MR, AGa, AGu, NBu, SA, VK, and DM were responsible for the study design and methodology and participated in the overall project design discussions. ADG, PC, DGP, CA, JG, LFR, CLHB, GC, LS, JTS, MG, DaBu, MGS, JOW, PO, and DMN participated in the CRF development and/or provided expert input at different stages of the project. EP implemented the computer code and supporting algorithms and tested of existing code components. DM and EP tested hypotheses and discussed statistical analyses. EP performed statistical analysis. The StopCOVID Research Team, NN, PBu, MA, AGa, AS, AB, PP, DBa, MP, EA, YF, and SD conducted a research and investigation process, specifically performed data extraction, telephone interviews, and data collection. VF, AAS, PT, LM, AM, ESa, SB, EB, AAK, DM, DB, and PG provided study materials, access to patient data, laboratory data, and computing resources. MA, ESp, PBo, PBu, YET, and MR managed activities to annotate metadata and maintain research data for initial use and later reuse. EP prepared visualisation and worked under DM supervision on the data presentation. DM was responsible for the oversight and leadership for the research activity planning and execution. DM, DB, PBo, ES, AS, AG, and EP provided management and coordination for the research activity planning and execution. VF, AAS, PT, IMO, DB, PG, and DM were responsible for the acquisition of the financial support for the project leading to this publication. EP, NN, and DM wrote original draft. All the authors critically reviewed and commented on the manuscript draft at both, pre-and post-submission stages. All authors read and approved the final manuscript.

No external funding.

Availability of data and materials

Declarations.

This study was approved by the Sechenov University Local Ethics Committee on April 22, 2020 (protocol number 08–20, protocol amendment enabling serial follow-up of the cohort was approved on November 13, 2020), and Moscow City Independent Ethics Committee (abbreviate 1, protocol number 74). Parental consent was sought during hospital admission, and consent for the follow-up interview was sought via verbal confirmation during telephone interview. The consent process was approved by the ethics.

Not applicable.

JTS is supported by Welcome. CLHB declares a grant from The Netherlands Organisation for Health Research and Development. CA declares grant by Federal Ministry of Education and Research (BMBF) for EgePan Unimed project involving research activities on post-COVID-19 condition received by his institution. JG declares grants from the German Federal Ministry of Education and Research, German Federal Ministry of Health, and Danone Nutricia Research reception by his institution. He also reports Danone Nutricia Research patents in the area of breast milk composition pending. He acknowledges receiving an honorarium for serving as an Associate Editor for the Journal Pediatric Allergy and Immunology. MGS reports grants from the National Institute of Health Research UK, Medical Research Council UK, and Health Protection Research Unit in Emerging & Zoonotic Infections, University of Liverpool. He is also an independent external and non-remunerated member of Pfizer’s External Data Monitoring Committee for their mRNA vaccine program(s), a Chair of Infectious Disease Scientific Advisory Board of Integrum Scientific LLC, Greensboro, NC, USA, director of MedEx Solutions Ltd. He also declares being a minority owner at Integrum Scientific LLC, Greensboro, NC, USA, and majority owner at MedEx Solutions Ltd. He reports that a gift from Chiesi Farmaceutici S.p.A. was received by his Institution of Clinical Trial Investigational Medicinal Product without encumbrance and distribution of same to trial sites. He also serves as a non-remunerated independent member of HMG UK Scientific Advisory Group for Emergencies (SAGE), COVID-19 Response, and HMG UK New Emerging Respiratory Virus Threats Advisory Group (NERVTAG). LS declares project funding from the Welcome Trust. DB has participated to a peer-to-peer (PAACE) educational program on long COVID, sponsored by Pfizer. JOW reports funding from Danone/Nutricia, Friesland-Campina, and Airsonett. He also serves an Anaphylaxis Campaign clinical and scientific panel chairman and acknowledges travel expenses as a speaker covered by the World Allergy Organisation. DM reports receipt of grants from the British Embassy in Moscow, UK National Institute for Health Research (NIHR) and Russian Foundation for Basic Research. He also Co-Chair of International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) Global Paediatric Long COVID Working Group, member of ISARIC working group on long-term follow-up in adults, and co-lead of the PC-COS project. Other authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ekaterina Pazukhina, Margarita Andreeva, Ekaterina Spiridonova, Polina Bobkova, Anastasia Shikhaleva, Yasmin El-Taravi, Mikhail Rumyantsev, Aysylu Gamirova, Ismail M Osmanov, and Daniel Munblit contributed equally to the paper.

Contributor Information

Sechenov StopCOVID Research Team: Nikol Alekseeva , Elena Artigas , Asmik Avagyan , Lusine Baziyants , Anna Belkina , Anna Berbenyuk , Tatiana Bezbabicheva , Vadim Bezrukov , Semyon Bordyugov , Aleksandra Borisenko , Maria Bratukhina , Ekaterina Bugaiskaya , Julia Chayka , Yulia Cherdantseva , Natalia Degtyareva , Olesya Druzhkova , Alexander Dubinin , Khalisa Elifkhanova , Dmitry Eliseev , Anastasia Ezhova , Aleksandra Frolova , Julia Ganieva , Anastasia Gorina , Cyrill Gorlenko , Elizaveta Gribaleva , Eliza Gudratova , Shabnam Ibragimova , Khadizhat Kabieva , Yulia Kalan , Margarita Kalinina , Nadezhda Khitrina , Bogdan Kirillov , Herman Kiseljow , Maria Kislova , Natalya Kogut , Irina Konova , Mariia Korgunova , Anastasia Kotelnikova , Karina Kovygina , Alexandra Krupina , Anastasia Kuznetsova , Anna Kuznetsova , Baina Lavginova , Elza Lidjieva , Ekaterina Listovskaya , Maria Lobova , Maria Loshkareva , Ekaterina Lyubimova , Daria Mamchich , Nadezhda Markina , Anastasia Maystrenko , Aigun Mursalova , Evgeniy Nagornov , Anna Nartova , Daria Nikolaeva , Georgiy Novoselov , Marina Ogandzhanova , Anna Pavlenko , Olga Perekosova , Erika Porubayeva , Kristina Presnyakova , Anna Pushkareva , Olga Romanova , Philipp Roshchin , Diana Salakhova , Ilona Sarukhanyan , Victoria Savina , Jamilya Shatrova , Nataliya Shishkina , Anastasia Shvedova , Denis Smirnov , Veronika Solovieva , Olga Spasskaya , Olga Sukhodolskaya , Shakir Suleimanov , Nailya Urmantaeva , Olga Usalka , Valeria Ustyan , Yana Valieva , Katerina Varaksina , Maria Varaksina , Ekaterina Varlamova , Maria Vodianova , Margarita Yegiyan , Margarita Zaikina , Anastasia Zorina , and Elena Zuykova

Got any suggestions?

We want to hear from you! Send us a message and help improve Slidesgo

Top searches

Trending searches

90 templates

welcome back to school

109 templates

meet the teacher

31 templates

35 templates

38 templates

classroom rules

5 templates

Linear COVID-19 Prevention

It seems that you like this template, free google slides theme, powerpoint template, and canva presentation template.

Currently, all information concerning preventive measures against COVID-19 is crucial and should be accessible for everybody. Explain them in the form of infographics, since images convey a lot. Edit our linear-style timelines, charts and diagrams to maximize the chances of your message reaching the public.

Features of these infographics

• 100% editable and easy to modify
• 30 different infographics to boost your presentations
• Include icons and Flaticon’s extension for further customization
• Designed to be used in Google Slides, Canva, and Microsoft PowerPoint and Keynote
• 16:9 widescreen format suitable for all types of screens
• Include information about how to edit and customize your infographics

How can I use the infographics?

Am I free to use the templates?

How to attribute the infographics?

Attribution required If you are a free user, you must attribute Slidesgo by keeping the slide where the credits appear. How to attribute?

Register for free and start downloading now

Related posts on our blog.

How to Add, Duplicate, Move, Delete or Hide Slides in Google Slides

How to Change Layouts in PowerPoint

How to Change the Slide Size in Google Slides

Related presentations.

Premium template

Unlock this template and gain unlimited access

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings
• My Bibliography
• Collections
• Citation manager

Save citation to file

Email citation, add to collections.

• Create a new collection
• Add to an existing collection

Add to My Bibliography

Your saved search, create a file for external citation management software, your rss feed.

• Search in PubMed
• Search in NLM Catalog
• Add to Search

Clinical course and outcome of patients with ACTH-dependent Cushing's syndrome infected with novel coronavirus disease-19 (COVID-19): case presentations

Affiliations.

• 1 The National Medical Research Center for Endocrinology, Moscow, Russia. [email protected].
• 2 I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.
• 3 The National Medical Research Center for Endocrinology, Moscow, Russia.
• 4 Clinical State Hospital named after SP Botkin, Moscow, Russia.
• 5 Life Sciences Research Center, Moscow Institute of Physics and Technology, Dolgoprudniy, Russia.
• PMID: 33713312
• PMCID: PMC7955209
• DOI: 10.1007/s12020-021-02674-5

Objective: To analyze the clinical presentations of patients with endogenous Cushing's syndrome (CS) affected by Coronavirus disease-19 (COVID-19).

Materials and methods: Patients who were referred to our clinic with active CS from 31st March to 15th May 2020 were screened for COVID-19 using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Late-night serum cortisol (64-327 nmol/L), late-night salivary cortisol (LNSC) (0.5-9.4 nmol/L), or 24-h urinary free cortisol (24 hUFC) (100-379 nmol/24 h) were measured by electrochemiluminescence immunoassay.

Results: Among 22 patients with active CS we found three cases affected by COVID-19. Nonspecific inflammation markers were within the reference range or slightly elevated in these patients. A 71-year-old woman with newly diagnosed CS (late-night serum cortisol >1750 nmol/L, LNSC 908.6 nmol/L) developed dyspnea as an only symptom and died from bilateral polysegmantal hemorrhagic pneumonia 7 days later. A 38-year-old woman with a 5-year medical history of active Cushing's disease (CD) (late-night serum cortisol 581.3 nmol/L, 24 hUFC 959.7 nmol/24-h) suffered from dyspnea, cough, fever (39.3 °C) and chest pain. Oxygen therapy, antibiotics and symptomatic treatments lead to full recovery 24 days later. A 66-year-old woman with a 4-year medical history of mild CD (late-night serum cortisol 603.4 nmol/L, LNSC 10.03 nmol/L) tested positive for COVID-19 in routine screening and remained asymptomatic.

Conclusions: The outcome of COVID-19 in patients with CS depends on the severity of hypercortisolism. Thus, severe hypercortisolism is a warning sign that CS affected by COVID-19 could require emergency care despite a lack of clinical presentations and low inflammation biomarkers.

Keywords: ACTH-dependent Cushing’s syndrome; COVID-19; Cushing’s disease; Pneumonia; SARS-CoV-2.

PubMed Disclaimer

Similar articles

• Late-night salivary cortisol as a screening test for Cushing's syndrome. Raff H, Raff JL, Findling JW. Raff H, et al. J Clin Endocrinol Metab. 1998 Aug;83(8):2681-6. doi: 10.1210/jcem.83.8.4936. J Clin Endocrinol Metab. 1998. PMID: 9709931
• The diagnostic accuracy of increased late night salivary cortisol for Cushing's syndrome: a real-life prospective study. Ceccato F, Marcelli G, Martino M, Concettoni C, Brugia M, Trementino L, Michetti G, Arnaldi G. Ceccato F, et al. J Endocrinol Invest. 2019 Mar;42(3):327-335. doi: 10.1007/s40618-018-0921-1. Epub 2018 Jul 9. J Endocrinol Invest. 2019. PMID: 29987756
• Cushing's Syndrome: Screening and Diagnosis. Ceccato F, Boscaro M. Ceccato F, et al. High Blood Press Cardiovasc Prev. 2016 Sep;23(3):209-15. doi: 10.1007/s40292-016-0153-4. Epub 2016 May 9. High Blood Press Cardiovasc Prev. 2016. PMID: 27160717 Review.
• Concordance of the late night salivary cortisol in patients with Cushing's syndrome and elevated urine-free cortisol. Doi SA, Clark J, Russell AW. Doi SA, et al. Endocrine. 2013 Apr;43(2):327-33. doi: 10.1007/s12020-012-9855-0. Epub 2012 Dec 14. Endocrine. 2013. PMID: 23238876
• Late Night Salivary Cortisol in the diagnosis of neoplastic hypercortisolism (including cyclic Cushing's syndrome). Raff H. Raff H. Pituitary. 2022 Oct;25(5):698-700. doi: 10.1007/s11102-022-01214-2. Epub 2022 Mar 25. Pituitary. 2022. PMID: 35334030 Review.
• COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders. Cozzolino A, Hasenmajer V, Newell-Price J, Isidori AM. Cozzolino A, et al. Endocrine. 2023 Oct;82(1):1-14. doi: 10.1007/s12020-023-03411-w. Epub 2023 Jun 20. Endocrine. 2023. PMID: 37338722 Free PMC article. Review.
• Epidemiology, course, and outcomes of Sars-CoV-2 infection in patients with acromegaly and Cushing's disease: a monocentric experience in Southern Italy. Ragonese M, Giuffrida G, Alessi Y, Giandalia A, Giovinazzo S, Cotta OR, Certo R, Casablanca R, Ferraù F, Cannavò S. Ragonese M, et al. J Endocrinol Invest. 2023 Aug;46(8):1711-1715. doi: 10.1007/s40618-023-02016-4. Epub 2023 Jan 28. J Endocrinol Invest. 2023. PMID: 36708457 Free PMC article.
• [Pituitary and COVID-19: review]. Buyvalenko UV, Perepelova MA, Zolotareva RA, Belaya ZE, Melnichenko GA. Buyvalenko UV, et al. Probl Endokrinol (Mosk). 2022 Jul 20;68(5):14-23. doi: 10.14341/probl13108. Probl Endokrinol (Mosk). 2022. PMID: 36337014 Free PMC article. Review. Russian.
• New Insights on Effects of Glucocorticoids in Patients With SARS-CoV-2 Infection. Shacham EC, Ishay A. Shacham EC, et al. Endocr Pract. 2022 Oct;28(10):1100-1106. doi: 10.1016/j.eprac.2022.07.006. Epub 2022 Jul 21. Endocr Pract. 2022. PMID: 35870803 Free PMC article. Review.
• [Hypophysitis and reversible hypopituitarism developed after COVID-19 infection - a clinical case report]. Gorbova NY, Vladimirova VP, Rozhinskaya LY, Belaya ZY. Gorbova NY, et al. Probl Endokrinol (Mosk). 2022 Mar 24;68(3):50-56. doi: 10.14341/probl12896. Probl Endokrinol (Mosk). 2022. PMID: 35841168 Free PMC article. Russian.
• N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med (2020). 10.1056/NEJMoa2001017. - PMC - PubMed
• W.J. Wiersinga, A. Rhodes, A.C. Cheng, S.J. Peacock, H.C Prescott. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA (2020). 10.1001/jama.2020.12839. - PubMed
• R. Mao, Y. Qiu, J.-S. He, J.-Y. Tan, X.-H. Li, J. Liang, J. Shen, L.-R. Zhu, Y. Chen, M. Iacucci, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. (2020). 10.1016/S2468-1253(20)30126-6. - PMC - PubMed
• M. Levi, J. Thachil, T. Iba, J.H. Levy. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet HaematoL. (2020). 10.1016/S2352-3026(20)30145-9. - PMC - PubMed
• Maggo S, Dhull P, Dubey AP, Brashier D, Karan A, Singh NK, Joshi K. Cytokine storm syndrome in COVID-19: diagnosis and management strategies. Int. J. Health Sci. Res. 2020;10:140–149.

Publication types

• Search in MeSH

Related information

• PubChem Compound (MeSH Keyword)

LinkOut - more resources

Full text sources.

• Europe PubMed Central
• PubMed Central

Other Literature Sources

• scite Smart Citations
• Genetic Alliance
• MedlinePlus Health Information

Miscellaneous

• NCI CPTAC Assay Portal
• Citation Manager

NCBI Literature Resources

MeSH PMC Bookshelf Disclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.